Buying a Biotech
Executive SummaryPrice premiums of recent biotech deals stay within a relatively narrow band, noted Rajen Dalal of Chiron at a recent dealmaking conference.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.